Oncology Voice Network
Join to access to all OVN content. Join for Free
Learn How Nurse Practitioners Use Biomarker Testing in Cancer Care

Learn How Nurse Practitioners Use Biomarker Testing in Cancer Care

  • by The Oncology Nursing Podcast
  • Mar 29th 2024
  • 38 mins
  • Episode 180

Share This Article

ONS members Kristin Daly, MSN, ANP-BC, AOCNP®, medical oncology nurse practitioner at the Siteman Cancer Center at the Washington University School of Medicine in St. Louis, MO, and Jessica Pforr, RN, AOCNP®, nurse practitioner at Mon Medical Center in Morgantown, WV, join Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss biomarker testing, interpreting test results, and how nurse practitioners working in academic and community settings can communicate testing results to their patients. AstraZeneca sponsored this podcast episode, which is brought to you by ONS.

Listen on Amazon Music, Listen on Apple Podcasts, Listen on Spotify, Listen on YouTube Music

Click for Source

Related Topics

Explore the Ecosystem

Meet Our Innovation Partners

You May Also Like

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Apr 8th • 4 mins • read
Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Apr 7th • 12 mins • read
Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

May 6th • 18 mins • read
Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

May 16th • 5 mins • read
Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Sep 3rd • 1 min • read
Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Feb 23rd • 8 mins • read

Explore OVN

Articles Expert-written insights
Browse Topics Oncology focus areas
OVN Podcast Flagship show
Community Why join OVN